Abstract
The relationship between doctors and drug companies is the subject of intense scrutiny—there is widespread skepticism about the intent of industry and concern for the vulnerability of doctors in the relationship. Unfortunately, the debate on how to move this relationship forward has become polarized: industry argues that collaboration with physicians is essential to scientific advancement, but at the same time many doctors are pledging to cut all their ties to drug companies (see, for example, the No Free Lunch pledge at http://www.nofreelunch.org/pledge.htm).
| Original language | English |
|---|---|
| Article number | e1000075 |
| Pages (from-to) | 1-4 |
| Number of pages | 4 |
| Journal | PLoS Medicine |
| Volume | 6 |
| Issue number | 7 |
| DOIs |
|
| Publication status | Published - Jul 2009 |
| Externally published | Yes |